{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116264","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.529710+00:00","generated_at":"2026-06-08T06:40:57.438303+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TELA Bio Q3 revenue $15.1M (+35% YoY); narrows FY2023 guidance to $57-60M","bullets":["Revenue of $15.1M, up 35% YoY, marking 11th straight quarter of ≥35% growth.","OviTex hernia mesh now #1 biologic mesh in U.S. by unit volume.","OviTex PRS revenue grew 46% YoY; commercial launch of Long-Term Resorbable variant.","Q3 net loss $11.0M vs. $10.7M a year ago; cash $58.2M at quarter end.","Updated FY2023 revenue guidance to $57-60M (38-45% YoY growth)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116264","json":"https://secwatch.observer/filing/0001104659-23-116264.json","markdown":"https://secwatch.observer/filing/0001104659-23-116264.md","text":"https://secwatch.observer/filing/0001104659-23-116264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/0001104659-23-116264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/tm2330287d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:40:57.438303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ef6c40bcb9d1c1ffc074049eeb7d4250cbb4ad0","claim":"TELA Bio, Inc. reported third quarter ended September 30, 2023 results: revenue $15.1 million, net income $11.0 million. Guidance reaffirmed.","evidence_excerpt":"the preservation and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights · Revenue of $15.1 million in the third quarter, representing growth of 35% over the third quarter of 2022 – the 11th consecutive quarter of 35% or greater year-over-year growth; · Demand for OviTex® and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/0001104659-23-116264-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$15.1 million"},{"label":"Net income","value":"$11.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}